% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Thierauf:120659,
      author       = {J. Thierauf and J. A. Veit and J. Hess$^*$ and N. Treiber
                      and C. Lisson and S. E. Weissinger and M. Bommer and T. K.
                      Hoffmann},
      title        = {{C}heckpoint inhibition for advanced mucosal melanoma.},
      journal      = {European journal of dermatology},
      volume       = {27},
      number       = {2},
      issn         = {1167-1122},
      address      = {Montrouge},
      publisher    = {Libbey Eurotext},
      reportid     = {DKFZ-2017-01086},
      pages        = {160-165},
      year         = {2017},
      abstract     = {Whereas anti-PD-1 therapy has demonstrated a significant
                      and durable response against advanced cutaneous melanoma,
                      conventional chemotherapies have shown only minor benefit
                      against advanced mucosal melanoma.To investigate the
                      efficacy of anti-PD-1 therapy in a small cohort of patients
                      with mucosal melanoma of the head and neck.We analysed five
                      patients with mucosal melanoma of the head and neck who
                      received nivolumab or pembrolizumab, at an advanced stage.
                      Expression of PD-L1 and PD-1 in all tumour samples was
                      evaluated immunohistochemically.All patients received at
                      least two cycles of nivolumab or pembrolizumab. The most
                      severe adverse events were categorised as CTCAE (common
                      terminology criteria for adverse events) Grade 2. All
                      patients showed progressive disease after restaging at three
                      and six months, and no partial or complete response was
                      observed. Immunohistochemical staining demonstrated PD-L1
                      expression in less than $5\%$ of tumour cells.Systemic
                      therapy with either nivolumab or pembrolizumab showed no
                      clinical response, however, tumour progression was
                      identified in all patients using Response Evaluation
                      Criteria In Solid Tumors (RECIST) v1.1 and immune-related
                      response criteria (irRC) to evaluate tumour response.},
      cin          = {G405},
      ddc          = {610},
      cid          = {I:(DE-He78)G405-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28174141},
      url          = {https://inrepo02.dkfz.de/record/120659},
}